UNSPSC 51352418: Ethynodiol/mestranol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352418 Ethynodiol/mestranol is a Commodity code that encompasses specific oral contraceptive formulations supplied to state and local government health benefit programs, public health agencies, and cooperative purchasing alliances. State and local governments purchase this pharmaceutical product both as part of broader generic pharmaceutical procurement initiatives and through direct-to-manufacturer pharmacy initiatives designed to improve prescription fulfillment efficiency and cost management. Issuing bodies include state health and human services departments and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and participating agencies, including employee health plans, Medicaid programs, and other public health benefit systems.

Recent activity centers on Texas and Minnesota. The Texas Health and Human Services Commission posted a Request for Information (RFI) in April 2026 (HHS0017013) exploring vendors' capabilities for direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, including Oregon; awarded vendors must supply through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dick Co., LLC, with contracts effective July 1, 2026. Both solicitations emphasize price competitiveness, regulatory compliance (cGMP and DSCSA for MMCAP), and integration with existing or proposed pharmacy distribution networks.